Skip to main content Skip to main navigation menu Skip to site footer

Profile of melasma patients in dermatology and venerology outpatient clinic Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

  • Aprilin Krista Devi ,
  • Budi Utomo ,
  • Diah Mira Indramaya ,
  • Muhammad Yulianto Listiawan ,
  • Sawitri ,
  • Dwi Murtiastutik ,
  • Cita Rosita Sigit Prakoeswa ,


Abstract

Background: Melasma is characterized by symmetrical brownish macules with well-defined borders. The etiology of melasma is still unknown, but factors that are thought to influence include genetic predisposition, ultraviolet radiation, hormonal factors, thyroid disorders, use of cosmetics, and drugs. This study aimed to determine the epidemiological data, evaluate risk factors, management, and follow-up in new melasma patients.

Methods: The medical records of patients with melasma attending Dermatology and Venereology Outpatient Clinic over a 4-year period from 2015 to 2018 were analyzed retrospectively for this descriptive, observational study. Data were analyzed using SPSS version 23 for Windows.

Results: This study found 739 new melasma patients from January 2015 to December 2018, with the proportion of women 734 patients (99.3%) more than men only 5 patients (0,7%). The age of most patients who were treated was 46-55 years in 320 patients (43.3%), with the highest age of onset being 37-45 years in 308 patients (41.7%). About 561 patients (75.9%) had a melasma duration of more than 1 year. The most common job of melasma patients was housewives in 366 patients (49.5%). The most frequent risk factor for melasma was ultraviolet radiation in 258 patients (34.9%). The most common melasma was malar type in 482 patients (65.2%) and mixed melasma in 617 patients (83.4%). The most widely administered therapy was sunscreen in 735 patients (99.5%) and Tretinoin 0.05% in 235 patients (31.8%). Most patients did not make repeat visits as many as 448 patients (60.6%).

Conclusion: The most common disease in women of childbearing age with ultraviolet radiation is the most precipitating risk factor. The low number of patient repeat visits can be caused by a lack of doctor education or a lack of patient adherence to treatment due to chronic and recurrent diseases.

Keywords: Melasma Epidemiology Risk Factors Therapy human and disease

References

  1. Mahdalena, Jusuf NK, Putra IB. Melasma characteristic in hormonal contraceptive acceptors at Kelurahan Mangga Kecamatan Medan Tuntungan, Medan-Indonesia. Bali Medical Journal. 2018;7(3):645-649.
  2. Rajanala S, Maymone MBC, Vashi NA. Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies. Dermatol Online J. 2019;25(10):13030/qt47b7r28c.
  3. Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. Dermatol Ther (Heidelb). 2017;7(3):305-318.
  4. Murniastuti DS, Etnawati K, Pudjiati SR. The correlation between severity of melasma with facial wrinkles in Yogyakarta, Indonesia. Dermatol Reports. 2020;12(2):8390.
  5. Doolan BJ, Gupta M. Melasma. Aust J Gen Pract. 2021;50(12):880-885.
  6. Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma (review). Cochrane Library. 2010;7(7):1-2.
  7. Asditya A, Sukanto H. Profile of melasma patients: a retrospective study. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2017;29(3):220-227.
  8. Choubey V, Sarkar R, Garg V, Kaushik S, Ghunawat S, Sonthalia S. Role of oxidative stress in melasma: a prospective study on serum and blood markers of oxidative stress in melasma patients. Int J Dermatol. 2017;56(9):939-943.
  9. Filoni A, Mariano M, Cameli N. Melasma: How hormones can modulate skin pigmentation. J Cosmet Dermatol. 2019;18(2):458-463.
  10. Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T, Kolbe L. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol. 2019;139(8):1691-1698.e6.
  11. Sarkar R, Jagadeesan S, Basavapura Madegowda S, Verma S, Hassan I, Bhat Y, et al. Clinical and epidemiologic features of melasma: a multicentric cross-sectional study from India. Int J Dermatol. 2019;58(11):1305-1310.
  12. Nanjundaswamy BL, Joseph JM, Raghavendra KR. A clinicodermoscopic study of melasma in a tertiary care centre. Pigment International. 2017;4(2):98-103.
  13. Tekgöz E, Akıncıoğlu E, Çınar M, Yılmaz S. A case of exogenous ochronosis associated with hydroxychloroquine. Eur J Rheumatol. 2018;5(3):206-208.
  14. Cestari T, Arellano I, Hexsel D, Ortonne JP; Latin American Pigmentary Disorders Academy. Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(7):760-772.
  15. Sarkar R, Arora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. Indian Dermatol Online J. 2014;5(4):426-35.
  16. Kwon SH, Na JI, Choi JY, Park KC. Melasma: Updates and perspectives. Exp Dermatol. 2019;28(6):704-708.
  17. Aishwarya K, Bhagwat PV, John N. Current concepts in melasma-a review article. J Skin Sex Transm Dis. 2020;2(1):13-17.
  18. Lee AY. Recent progress in melasma pathogenesis. Pigment Cell Melanoma Res. 2015;28(6):648-660.
  19. Nahhas AF, Braunberger TL, Hamzavi IH. An Update on Drug-Induced Pigmentation. Am J Clin Dermatol. 2019;20(1):75-96.
  20. Fatima S, Braunberger T, Mohammad TF, Kohli I, Hamzavi IH. The Role of Sunscreen in Melasma and Postinflammatory Hyperpigmentation. Indian J Dermatol. 2020;65(1):5-10.
  21. McKesey J, Tovar-Garza A, Pandya AG. Melasma Treatment: An Evidence-Based Review. Am J Clin Dermatol. 2020;21(2):173-225.
  22. PERDOSKI. Panduan praktek klinis bagi dokter spesialis kulit dan kelamin di Indonesia. PERDOSKI. 2017:273-76.
  23. Sarma N, Chakraborty S, Poojary SA, Rathi S, Kumaran S, Nirmal B, et al. Evidence-based Review, Grade of Recommendation, and Suggested Treatment Recommendations for Melasma. Indian Dermatol Online J. 2017;8(6):406-442.
  24. Zhang Y, Zheng X, Chen Z, Lu L. Laser and laser compound therapy for melasma: a meta-analysis. J Dermatolog Treat. 2020;31(1):77-83.
  25. Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(1):78-83.

How to Cite

Devi, A. K., Utomo, B., Indramaya, D. M., Listiawan, M. Y., Sawitri, Murtiastutik, D., & Prakoeswa, C. R. S. (2022). Profile of melasma patients in dermatology and venerology outpatient clinic Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Bali Medical Journal, 11(1), 166–173. https://doi.org/10.15562/bmj.v11i1.3182
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
1

Total
26

Share

Search Panel

Aprilin Krista Devi
Google Scholar
Pubmed
BMJ Journal

Budi Utomo
Google Scholar
Pubmed
BMJ Journal

Diah Mira Indramaya
Google Scholar
Pubmed
BMJ Journal

Muhammad Yulianto Listiawan
Google Scholar
Pubmed
BMJ Journal

Sawitri
Google Scholar
Pubmed
BMJ Journal

Dwi Murtiastutik
Google Scholar
Pubmed
BMJ Journal

Cita Rosita Sigit Prakoeswa
Google Scholar
Pubmed
BMJ Journal